Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of BGB-16673 versus pirtobrutinib in relapsed/refractory CLL or SLL after prior covalent BTK inhibitor
MOH_2025-11-09_015445Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2025
- Modality
- Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of catadegbrutinib and pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by BeOne Medicines. Started Oct 2025; status: recruiting.
02
Drugs
catadegbrutinibpirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2025-11-09_015445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-09_015445.